125 research outputs found
Combining Shamir & Additive Secret Sharing to Improve Efficiency of SMC Primitives Against Malicious Adversaries
Secure multi-party computation provides a wide array of protocols for
mutually distrustful parties be able to securely evaluate functions of private
inputs. Within recent years, many such protocols have been proposed
representing a plethora of strategies to securely and efficiently handle such
computation. These protocols have become increasingly efficient, but their
performance still is impractical in many settings. We propose new approaches to
some of these problems which are either more efficient than previous works
within the same security models or offer better security guarantees with
comparable efficiency. The goals of this research are to improve efficiency and
security of secure multi-party protocols and explore the application of such
approaches to novel threat scenarios. Some of the novel optimizations employed
are dynamically switching domains of shared secrets, asymmetric computations,
and advantageous functional transformations, among others. Specifically, this
work presents a novel combination of Shamir and Additive secret sharing to be
used in parallel which allows for the transformation of efficient protocols
secure against passive adversaries to be secure against active adversaries.
From this set of primitives we propose the construction of a comparison
protocol which can be implemented under that approach with a complexity which
is more efficient than other recent works for common domains of interest.
Finally, we present a system which addresses a critical security threat for the
protection and obfuscation of information which may be of high consequence.Comment: arXiv admin note: text overlap with arXiv:1810.0157
The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study
Radio astronomy
The following subject areas are covered: (1) scientific opportunities (millimeter and sub-millimeter wavelength astronomy; meter to hectometer astronomy; the Sun, stars, pulsars, interstellar masers, and extrasolar planets; the planets, asteroids, and comets; radio galaxies, quasars, and cosmology; and challenges for radio astronomy in the 1990's); (2) recommendations for new facilities (the millimeter arrays, medium scale instruments, and small-scale projects); (3) continuing activities and maintenance, upgrading of telescopes and instrumentation; (4) long range programs and technology development; and (5) social, political, and organizational considerations
An Assessment of Exposure Models for Bioengineered Microorganisms
Environmental risk assessment performed for chemicals involves exposure assessment, effects assessment, and risk integration. The nature of living microorganisms (growth, replication. and survival), as compared to chemicals, requires that their biological attributes be integrated into risk assessment. Biological attributes have generally been dealt with in effects assessment and not exposure assessment models. Thus, exposure assessment models that characterize source, transport, transformation, and fate (effective environmental concentration, area, and duration of exposure) of genetically engineered microorganisms must incorporate biological factors along with physicochemical factors.
A study to assess the state of the art of exposure models for organisms and microorganisms in air, soil, and water was undertaken. Mathematical models developed during the past 15 years were organized into three categories: organism population dynamics, source features and transport, and management and control. One hundred forty-eight models were examined, and 56 were judged to have potential as exposure models. These 56 were screened to 31 models that were then evaluated against eight components that the ideal biotechnology model should have: (a) five state/process components (organism population, source application, exposure site, movement, and imposed management) and (b) three software components (user friendliness, availability/implementability, and flexibility). Each model was rated by individual components, combinations of two components, and total state/process components. An ideal exposure assessment model with high scores in all components was not found.
Combining two or more models so that the strong components of one compensate for the weak components of another was concluded to be the best approach for obtaining a predictive model for microorganisms. Potential couplings were ascertained from among the 31 models. Most of these couplings would combine an organism population dynamics model with a model from the U. S. Environmental Protection Agency\u27s Graphical Exposure Modeling System (source and transport oriented models)
Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach
BACKGROUND: The World Health Organization (WHO) currently recommends height or age-based dosing as alternatives to weight-based dosing for mass drug administration lymphatic filariasis (LF) elimination programs. The goals of our study were to compare these alternative dosing strategies to weight-based dosing and to develop and evaluate new height-based dosing pole scenarios.
METHODOLOGY/PRINCIPAL FINDINGS: Age, height and weight data were collected from \u3e26,000 individuals in five countries during a cluster randomized LF clinical trial. Weight-based dosing for diethylcarbamazine (DEC; 6 mg/kg) and ivermectin (IVM; 200 ug/kg) with tablet numbers derived from a table of weight intervals was treated as the gold standard for this study. Following WHO recommended age-based dosing of DEC and height-based dosing of IVM would have resulted in 32% and 27% of individuals receiving treatment doses below those recommended by weight-based dosing for DEC and IVM, respectively. Underdosing would have been especially common in adult males, who tend to have the highest LF prevalence in many endemic areas. We used a 3-step modeling approach to develop and evaluate new dosing pole cutoffs. First, we analyzed the clinical trial data using quantile regression to predict weight from height. We then used weight predictions to develop new dosing pole cutoff values. Finally, we compared different dosing pole cutoffs and age and height-based WHO dosing recommendations to weight-based dosing. We considered hundreds of scenarios including country- and sex-specific dosing poles. A simple dosing pole with a 6-tablet maximum for both DEC and IVM reduced the underdosing rate by 30% and 21%, respectively, and was nearly as effective as more complex pole combinations for reducing underdosing.
CONCLUSIONS/SIGNIFICANCE: Using a novel modeling approach, we developed a simple dosing pole that would markedly reduce underdosing for DEC and IVM in MDA programs compared to current WHO recommended height or age-based dosing
A multi-center, open-labeled, cluster-randomized study of the safety of double and triple drug community mass drug administration for lymphatic filariasis
BackgroundThe Global Programme to Eliminate Lymphatic Filariasis (GPELF) provides antifilarial medications to hundreds of millions of people annually to treat filarial infections and prevent elephantiasis. Recent trials have shown that a single-dose, triple-drug treatment (ivermectin with diethylcarbamazine and albendazole [IDA]) is superior to a two-drug combination (diethylcarbamazine plus albendazole [DA]) that is widely used in LF elimination programs. This study was performed to assess the safety of IDA and DA in a variety of endemic settings.Methods and findingsLarge community studies were conducted in five countries between October 2016 and November 2017. Two studies were performed in areas with no prior mass drug administration (MDA) for filariasis (Papua New Guinea and Indonesia), and three studies were performed in areas with persistent LF despite extensive prior MDA (India, Haiti, and Fiji). Participants were treated with a single oral dose of IDA (ivermectin, 200 μg/kg; diethylcarbamazine, 6 mg/kg; plus albendazole, a fixed dose of 400 mg) or with DA alone. Treatment assignment in each study site was randomized by locality of residence. Treatment was offered to residents who were ≥5 years of age and not pregnant. Adverse events (AEs) were assessed by medical teams with active follow-up for 2 days and passive follow-up for an additional 5 days. A total of 26,836 persons were enrolled (13,535 females and 13,300 males). A total of 12,280 participants were treated with DA, and 14,556 were treated with IDA. On day 1 or 2 after treatment, 97.4% of participants were assessed for AEs. The frequency of all AEs was similar after IDA and DA treatment (12% versus 12.1%, adjusted odds ratio for IDA versus DA 1.15, 95% CI 0.87-1.52, P = 0.316); 10.9% of participants experienced mild (grade 1) AEs, 1% experienced moderate (grade 2) AEs, and 0.1% experienced severe (grade 3) AEs. Rates of serious AEs after DA and IDA treatment were 0.04% (95% CI 0.01%-0.1%) and 0.01% (95% CI 0.00%-0.04%), respectively. Severity of AEs was not significantly different after IDA or DA. Five of six serious AEs reported occurred after DA treatment. The most common AEs reported were headache, dizziness, abdominal pain, fever, nausea, and fatigue. AE frequencies varied by country and were higher in adults and in females. AEs were more common in study participants with microfilaremia (33.4% versus 11.1%, P ConclusionsIn this study, we observed that IDA was well tolerated in LF-endemic populations. Posttreatment AE rates and severity did not differ significantly after IDA or DA treatment. Thus, results of this study suggest that IDA should be as safe as DA for use as a MDA regimen for LF elimination in areas that currently receive DA.Trial registrationClinicaltrials.gov registration number: NCT02899936
Acoustic detection and quantification of benthic egg beds of the squid Loligo opalescens in Monterey Bay, California
Author Posting. © Acoustical Society of America, 2006. This article is posted here by permission of Acoustical Society of America for personal use, not for redistribution. The definitive version was published in Journal of the Acoustical Society of America 119 (2006): 844-856, doi:10.1121/1.2149840.The squid Loligo opalescens is a key species in the nearshore pelagic community of California, supporting the most valuable state marine fishery, yet the stock biomass is unknown. In southern Monterey Bay, extensive beds occur on a flat, sandy bottom, water depths 20–60 m, thus sidescan sonar is a prima-facie candidate for use in rapid, synoptic, and noninvasive surveying. The present study describes development of an acoustic method to detect, identify, and quantify squid egg beds by means of high-frequency sidescan-sonar imagery. Verification of the method has been undertaken with a video camera carried on a remotely operated vehicle. It has been established that sidescan sonar images can be used to predict the presence or absence of squid egg beds. The lower size limit of detectability of an isolated egg bed is about 0.5 m with a 400-kHz sidescan sonar used with a 50-m range when towed at 3 knots. It is possible to estimate the abundance of eggs in a region of interest by computing the cumulative area covered by the egg beds according to the sidescan sonar image. In a selected quadrat one arc second on each side, the estimated number of eggs was 36.5 million.funding from the National Sea Grant, Essential Fish Habitat
Program, Sea Grant Project No. NA16RG2273
The Azithromycin to Prevent Wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population
Severe respiratory syncytial virus (RSV) bronchiolitis in early life is a significant risk factor for future recurrent wheeze (RW) and asthma. The goal of the Azithromycin to Prevent Wheezing following severe RSV bronchiolitis II (APW-RSV II) clinical trial is to evaluate if azithromycin treatment in infants hospitalized with RSV bronchiolitis reduces the occurrence of RW during the preschool years. The APW-RSV II clinical trial is a double-blind, placebo-controlled, parallel-group, randomized trial, including otherwise healthy participants, ages 30 days-18 months, who are hospitalized due to RSV bronchiolitis. The study includes an active randomized treatment phase with azithromycin or placebo for 2 weeks, and an observational phase of 18-48 months. Two hundred participants were enrolled during three consecutive RSV seasons beginning in the fall of 2016 and were randomized to receive oral azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for an additional 7 days, or matched placebo. The study hypothesis is that in infants hospitalized with RSV bronchiolitis, the addition of azithromycin therapy to routine bronchiolitis care would reduce the likelihood of developing post-RSV recurrent wheeze (≥3 episodes). The primary clinical outcome is the occurrence of a third episode of wheezing, which is evaluated every other month by phone questionnaires and during yearly in-person visits. A secondary objective of the APW-RSV II clinical trial is to examine how azithromycin therapy changes the upper airway microbiome composition, and to determine if these changes are related to the occurrence of post-RSV RW. Microbiome composition is characterized in nasal wash samples obtained before and after the study treatments. This clinical trial may identify the first effective intervention applied during severe RSV bronchiolitis to reduce the risk of post-RSV RW and ultimately asthma
A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis
BackgroundMany countries will not reach elimination targets for lymphatic filariasis in 2020 using the two-drug treatment regimen (diethylcarbamazine citrate [DEC] and albendazole [DA]). A cluster-randomized, community-based safety study performed in Fiji, Haiti, India, Indonesia and Papua New Guinea tested the safety and efficacy of a new regimen of ivermectin, DEC and albendazole (IDA).Methodology/principal findingsTo assess acceptability of IDA and DA, a mixed methods study was embedded within this community-based safety study. The study objective was to assess the acceptability of IDA versus DA. Community surveys were performed in each country with randomly selected participants (>14 years) from the safety study participant list in both DA and IDA arms. In depth interviews (IDI) and focus group discussions (FGD) assessed acceptability-related themes. In 1919 individuals, distribution of sex, microfilariae (Mf) presence and circulating filarial antigenemia (CFA), adverse events (AE) and age were similar across arms. A composite acceptability score summed the values from nine indicators (range 9-36). The median (22.5) score indicated threshold of acceptability. There was no difference in scores for IDA and DA regimens. Mean acceptability scores across both treatment arms were: Fiji 33.7 (95% CI: 33.1-34.3); Papua New Guinea 32.9 (95% CI: 31.9-33.8); Indonesia 30.6 (95% CI: 29.8-31.3); Haiti 28.6 (95% CI: 27.8-29.4); India 26.8 (95% CI: 25.6-28) (PConclusions/significanceIDA and DA regimens for LF elimination were highly and equally acceptable in individuals participating in the community-based safety study in Fiji, Haiti, India, Indonesia, and Papua New Guinea. Country variation in acceptability was significant. Acceptability of the professionalism of the treatment delivery was highlighted
Genome Analyses of an Aggressive and Invasive Lineage of the Irish Potato Famine Pathogen
Pest and pathogen losses jeopardise global food security and ever since the 19th century Irish famine, potato late blight has exemplified this threat. The causal oomycete pathogen, Phytophthora infestans, undergoes major population shifts in agricultural systems via the successive emergence and migration of asexual lineages. The phenotypic and genotypic bases of these selective sweeps are largely unknown but management strategies need to adapt to reflect the changing pathogen population. Here, we used molecular markers to document the emergence of a lineage, termed 13_A2, in the European P. infestans population, and its rapid displacement of other lineages to exceed 75% of the pathogen population across Great Britain in less than three years. We show that isolates of the 13_A2 lineage are among the most aggressive on cultivated potatoes, outcompete other aggressive lineages in the field, and overcome previously effective forms of plant host resistance. Genome analyses of a 13_A2 isolate revealed extensive genetic and expression polymorphisms particularly in effector genes. Copy number variations, gene gains and losses, amino-acid replacements and changes in expression patterns of disease effector genes within the 13_A2 isolate likely contribute to enhanced virulence and aggressiveness to drive this population displacement. Importantly, 13_A2 isolates carry intact and in planta induced Avrblb1, Avrblb2 and Avrvnt1 effector genes that trigger resistance in potato lines carrying the corresponding R immune receptor genes Rpi-blb1, Rpi-blb2, and Rpi-vnt1.1. These findings point towards a strategy for deploying genetic resistance to mitigate the impact of the 13_A2 lineage and illustrate how pathogen population monitoring, combined with genome analysis, informs the management of devastating disease epidemic
- …